By Rex Clements, Head of Global Franchises at Sandoz.
Lord Jim O’Neill, the author of the UK government-commissioned Review on AMR, has called on the pharmaceutical industry to “think more broadly” about the role it can play in combatting the growing global threat of antimicrobial resistance (AMR).
Sheila Frame, VP and Head of Biopharmaceuticals in North America, reflects on the newly published RAND report highlighting the potential USD 54 billion in cost savings offered by the expansion of biosimilars in the US.
New data just released in the two largest global pharma markets show the substantial and growing level of savings made possible by increased use of generic medicines.
Taking a look back at the inaugural Healthcare Access Challenge (Sandoz HACk) – and a look forward at what comes next.
An ageing society and continuously rising healthcare costs pose significant challenges for healthcare systems and industry alike, and call for a change in how the pharmaceutical industry operates, says Sandoz Division Head and CEO Richard Francis.
This site is intended for a global audience